Current Status of Anti Epidermal Growth Factor Receptor Therapy in the Curative Treatment of Head and Neck Squamous Cell Carcinoma
DOI:
https://doi.org/10.17140/CSMMOJ-3-114Keywords:
Epidermal growth factor receptor (EGFR), Head and neck-targeted therapyAbstract
Squamous cell carcinoma of head and neck is the most common malignancy of the upper aero digestive tract in the world. In this article, we attempt to summarize the role of antiepidermal growth factor therapy (EGFR) in the treatment of locally advanced head and neck squamous cell carcinoma. Cetuximab plus radiotherapy is a reasonable alternative in patients who cannot tolerate standard concurrent chemoradiotherapy (CTRT). There is no benefit by adding targeted therapy in addition to standard CTRT. Trials evaluating the role of targeted agents in the adjuvant setting showed no benefit in patients with high risk features; in addition to standard post-operative CTRT. Role of adjuvant monoclonal antibody in patients with intermediate risk factors is being evaluated.
References
WHO. Globocan 2012. Estimated Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer. Web site. http://globocan.iarc.fr/Pages/ fact_sheets_cancer.aspx. Accessed January 29, 2016.
Kulkarni MR. Head and neck cancer burden in India. Int J Head Neck Surg. 2013; 4(1): 29-35. doi: 10.5005/10001-1132
NCCN. NCCN Clinical Practice Guidelines in Oncology. Version 2. 2015. Web site. http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp. Accessed January 29, 2016.
Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013; 31(7): 845-852. doi: 10.1200/ JCO.2012.43.6097
Pignon JP, le Maitre A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients. Radiother Oncol. 2009; 92(1): 4-14. doi: 10.1016/j.radonc.2009.04.014
Cohen EEW, Theodore G, et al. Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. J Clin Oncol. 2014; 32(25): 2735-2743. doi: 10.1200/JCO.2013.54.6309
Hitt R, Grau JJ, A. López-Pousa, et al. A randomized phase III trial comparing induction chemotherapy followed by chemo radiotherapy versus chemo radiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014; 25(1): 216-225. doi: 10.1093/annonc/mdt461
Haddad R, O’Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemo radiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomized phase 3 trial. Lancet Oncol. 2013; 14(3): 257-264. doi: 10.1016/S1470-2045(13)70011-1
Budach W, Bölke E, Kammers K, et al. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Radiother Oncol. 118(2): 238-243. doi: 10.1016/j.radonc.2015.10.014
Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62: 7350-7356. Web site. http://cancerres.aacrjournals. org/content/62/24/7350.long. Accessed January 29, 2016.
Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984; 44(3): 1002-1007. Web site. http://cancerres. aacrjournals.org/content/44/3/1002.long. Accessed January 29, 2016.
Mendelsohn J. Growth factor receptors as targets for anti-tumor therapy with Monoclonal antibodies. Prog Allergy. 1988; 45: 147-160.
Balaban N, Moni J, Shannon M, Dang L, Murphy E, Goldkorn T. The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta. 1996; 1314: 147-156.
Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 1997; 15: 1191-1197. Web site. http://www.nature.com/onc/ journal/v15/n10/abs/1201275a.html Accessed January 29, 2016.
Tan EH, Goh C, Lim WT, et al. Gefitinib, cisplatin, and concurrent radiotherapy For locally advanced head and neck cancer: EGFR FISH, protein expression, and Mutational status is not predictive biomarkers. Ann Oncol. 2012; 23(4): 1010- 1016. doi: 10.1093/annonc/mdr327
Harrington K, Berrier A, Robinson M, et al. Randomized Phase II study of oral lapatinib combined with chemo radiotherapy in patients with advanced Squamous cell carcinoma of the head and neck: rationale for future randomized Trials in human papilloma virus-negative disease. Eur J Cancer. 2013; 49(7): 1609-1618. doi: 10.1016/j.ejca.2012.11.023
Martins RG, Parvathaneni, Bauman JE, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J ClinOncol. 2013; 31(11): 1415-1421. doi: 10.1200/JCO.2012.46.3299
Reddy BK Lokesh V, Vidyasagar MS, et al. Nimotuzumab provides survival Benefit to patients with inoperable advanced squamous cell carcinoma of the Head and Neck: a randomized, open-label, phase II, 5-year study in Indian patients. Oral Oncol. 2014; 50(5): 498-505. doi: 10.1016/j. oraloncology.2013.11.008
Mesía R, Henke M, Fortin A, et al. Chemo radiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the Head and neck (CONCERT-1): a randomized, controlled, open-label phase 2 trial. Lancet Oncol. 2015; 16(2): 208-220. doi: 10.1016/S1470- 2045(14)71198-2
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for Squamous cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-578. doi: 10.1056/NEJMoa053422
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for loco regionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial and relation between cetuximab induced rash and survival. Lancet Oncol. 2010; 11: 21-28. doi: 10.1016/S1470-2045(09)70311-0
Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent Accelerated Radiation PlusCisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014; 8(25): 2940-2950; doi: 10.1200/JCO.2013.53.5633
Siu LL, Waldron JN, Chen BE, et al. Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with loco regionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. J Clin Oncol. 2015; (suppl; abstr 6000).
Trotti A. Phase III Trial of Radiotherapy plus Cetuximab versus Chemoradiotherapy in Hpv-Associated Oropharynx Cancer, RTOG 1016. J Clin Oncol. 2014; 32:5s-32:5s.
Tupchong L, Scott CB, Blitzer PH, et al. Randomized study of preoperative versus Postoperative radiation therapy in advanced head and neck carcinoma: Long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys. 1991; 20: 21- 28. doi: 10.1016/0360-3016(91)90133-O
Peters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative Radiation therapy of head and neck cancer: First report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993; 26: 3-11. doi: 10.1016/0360-3016(93)90167-T
Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012; 84(5):1198-1205. doi: 10.1016/j.ijrobp.2012.05.008
Bernie J. Postoperative Irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350(19): 1945-1952. doi: 10.1056/ NEJMoa032641
Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck. 2005; 27: 843-850. doi: 10.1002/hed.20279
Machtay M. A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer. RTOG 0920 clinical trials.gov, NCT00956007. Web site. https://clinicaltrials.gov/ct2/show/ NCT00956007. Accessed January 29, 2016.
Harari PM, Harris J, Kies MS, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014; 32(23): 2486-2495. doi: 10.1200/JCO.2013.53.9163
Harrington KJ, Temam S, D’Cruz A, et al. Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2014; 32: 5s (suppl; abstr 6005).
Soo KC, Tan EH. Phase III, double-blind, placebo-controlled study of post-operative adjuvant concurrent chemo-radiotherapy with or without nimotuzumab for stage III/IV head and neck squamous cell cancer. Clinical trials.gov NCT00957086. Web site. https://clinicaltrials.gov/ct2/show/NCT00957086. Accessed January 29, 2016.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
